Sjögren's disease & overlap diseases
Anti-SSA Ro52 and anti-Ro60 autoantibodies: association with clinical phenotypes
Authors' conclusion
Anti-Ro52+ antibody alone is frequently found in patients with non-rheumatic diseases. In addition, anti-Ro52+ antibody is also prevalent in patients with CTD and associated with clinical phenotypes that are different from anti-Ro60+ antibody.
Study context
- Population
- Patients positive for anti-Ro52 and/or Ro60 antibodies followed at 10 rheumatology centres, January 2018 to December 2021female: 83.1%
- Participants
- 776 participants
- Exposure
- Ro52+/Ro60- vs Ro52-/Ro60+ vs Ro52+/Ro60+
- Outcome
- Disease phenotype by anti-Ro52/anti-Ro60 antibody group
Methodological detailsmulticentre, logistic regression
- Multicentre
- Logistic regression
Main finding
As reported in the abstract
Clinical phenotype by anti-Ro52/anti-Ro60 profile
Each group vs group 1Odds ratio (95% CI)P value
Group 2SLE diagnosis among patients with CTD
2.8(1.60–4.97)
P < 0.001Group 3SLE diagnosis among patients with CTD
2.2(1.28–3.86)
P < 0.01Group 2Inflammatory myositis; Group 1 more frequently associated
0.09(0.01–0.33)
P < 0.001Group 3Inflammatory myositis; Group 1 more frequently associated
0.08(0.01–0.29)
P < 0.001- Anti-Ro52 alone more frequently associated with non-rheumatic diseases, older age and men
- P < 0.05
- Group 1 more frequently associated with arthritis
- P < 0.01
- Group 1 more frequently associated with ILD
- P < 0.01
- Group 1 more frequently associated with myositis
- P < 0.01
Observational data: associations, not effects.
Further findings
Undifferentiated connective tissue diseases (CTD)
- More frequent in group 2 than in the other groups
Arthritis, ILD and myositis
- Group 1 more frequently associated with arthritis
- P < 0.01
- Group 1 more frequently associated with ILD
- P < 0.01
- Group 1 more frequently associated with myositis
- P < 0.01
Original publication
Anti-SSA Ro52 and anti-Ro60 autoantibodies: association with clinical phenotypes. Clin Exp Rheumatol. Published 11 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →